• Something wrong with this record ?

Intracardiac echocardiography-guided implantation of the Watchman FLX left atrial appendage closure device

MK. Turagam, P. Neuzil, J. Petru, P. Hala, T. Mraz, J. Baroch, V. Lekesova, M. Prokopova, SR. Dukkipati, VY. Reddy

. 2021 ; 32 (3) : 717-725. [pub] 20210210

Language English Country United States

Document type Journal Article

BACKGROUND: The next-generation Watchman FLX left atrial appendage closure (LAAC) device has: (1) an atraumatic closed distal end, (2) reduced height, (3) a recessed screw hub to decrease device-related thrombus (DRT), (4) two rows of J-shape anchors so redeployment is possible after full recapture, and (5) ability to treat a greater size range of LAA ostia. OBJECTIVE: To report, for the first time, the feasibility and safety of intracardiac echocardiography (ICE)-guided Watchman FLX implantation. METHODS: A single-center prospective registry of atrial fibrillation patients planned for LAAC with the FLX device underwent ICE-guided implantation with conscious sedation. Transesophageal echocardiography (TEE) imaging was done preprocedure (to assess LAA size and exclude thrombus) and at clinical follow-up at 6-12 weeks. Clinical outcomes were LAA closure success, complications, leak, or DRT on follow-up TEE and major safety events. RESULTS: The study included 30 patients: age 75 ± 8 years, 53% men, CHA2 DS2 -VASc 4.6 ± 1.6, and HAS-BLED 3.4 ± 1.1. The primary indication was prior bleeding in 60% (72% GI bleeding). The LAA orifice width and length were 22.7 ± 3.1 and 25.7 ± 5.7 mm, respectively. Technical success was 100% (the first-choice device was used in 28 of 30). Procedure time was less than 30 min in 27 of 30 cases, with 36 ± 15 ml contrast used. The final device size was 29.2 ± 4.7 mm with 21.6 ± 4.5% compression. There were no procedure-related complications. Follow-up TEE at a median 47 days follow-up showed 100% device success with no DRT or peridevice leak ≥5 mm. Major safety events occurred in 6.6% (2/30). CONCLUSION: The Watchman FLX device can be safely implanted with intraprocedural ICE imaging instead of TEE.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026021
003      
CZ-PrNML
005      
20211026133253.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jce.14927 $2 doi
035    __
$a (PubMed)33533089
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Turagam, Mohit K $u Department of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
245    10
$a Intracardiac echocardiography-guided implantation of the Watchman FLX left atrial appendage closure device / $c MK. Turagam, P. Neuzil, J. Petru, P. Hala, T. Mraz, J. Baroch, V. Lekesova, M. Prokopova, SR. Dukkipati, VY. Reddy
520    9_
$a BACKGROUND: The next-generation Watchman FLX left atrial appendage closure (LAAC) device has: (1) an atraumatic closed distal end, (2) reduced height, (3) a recessed screw hub to decrease device-related thrombus (DRT), (4) two rows of J-shape anchors so redeployment is possible after full recapture, and (5) ability to treat a greater size range of LAA ostia. OBJECTIVE: To report, for the first time, the feasibility and safety of intracardiac echocardiography (ICE)-guided Watchman FLX implantation. METHODS: A single-center prospective registry of atrial fibrillation patients planned for LAAC with the FLX device underwent ICE-guided implantation with conscious sedation. Transesophageal echocardiography (TEE) imaging was done preprocedure (to assess LAA size and exclude thrombus) and at clinical follow-up at 6-12 weeks. Clinical outcomes were LAA closure success, complications, leak, or DRT on follow-up TEE and major safety events. RESULTS: The study included 30 patients: age 75 ± 8 years, 53% men, CHA2 DS2 -VASc 4.6 ± 1.6, and HAS-BLED 3.4 ± 1.1. The primary indication was prior bleeding in 60% (72% GI bleeding). The LAA orifice width and length were 22.7 ± 3.1 and 25.7 ± 5.7 mm, respectively. Technical success was 100% (the first-choice device was used in 28 of 30). Procedure time was less than 30 min in 27 of 30 cases, with 36 ± 15 ml contrast used. The final device size was 29.2 ± 4.7 mm with 21.6 ± 4.5% compression. There were no procedure-related complications. Follow-up TEE at a median 47 days follow-up showed 100% device success with no DRT or peridevice leak ≥5 mm. Major safety events occurred in 6.6% (2/30). CONCLUSION: The Watchman FLX device can be safely implanted with intraprocedural ICE imaging instead of TEE.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a síňové ouško $x diagnostické zobrazování $x chirurgie $7 D020517
650    12
$a fibrilace síní $x diagnostické zobrazování $x chirurgie $7 D001281
650    _2
$a srdeční katetrizace $x škodlivé účinky $7 D006328
650    _2
$a echokardiografie transezofageální $7 D017548
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a cévní mozková příhoda $7 D020521
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Neuzil, Petr $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Petru, Jan $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Hala, Pavel $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Mraz, Tomas $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Baroch, Jiri $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Lekesova, Veronika $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Prokopova, Milena $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
700    1_
$a Dukkipati, Srinivas R $u Department of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Reddy, Vivek Y $u Department of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA $u Department of Cardiovascular Medicine, Homolka Hospital, Prague, Czech Republic
773    0_
$w MED00002569 $t Journal of cardiovascular electrophysiology $x 1540-8167 $g Roč. 32, č. 3 (2021), s. 717-725
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33533089 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133259 $b ABA008
999    __
$a ok $b bmc $g 1714897 $s 1146528
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 32 $c 3 $d 717-725 $e 20210210 $i 1540-8167 $m Journal of cardiovascular electrophysiology $n J Cardiovasc Electrophysiol $x MED00002569
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...